Insulin Resistance during normal child growth and development is associated with a distinct blood metabolic phenotype (Earlybird 72) by Hosking, J et al.
OB E S I T Y / I N S U L I N R E S I S T AN C E , T Y P E 2 D I A B E T E S
Insulin Resistance during normal child growth and
development is associated with a distinct blood metabolic
phenotype (Earlybird 72)
Joanne Hosking1 | Jonathan Pinkney1 | Alison Jeffery1 | Ornella Cominetti2 |
Laeticia Da Silva2 | Sebastiano Collino2 | Martin Kussmann2 | Jorg Hager3 |
Francois-Pierre Martin4
1Faculty of Medicine and Dentistry, Plymouth
University, Plymouth, UK
2Department of Analytical Sciences, Société
des Produits Nestlé SA, Nestlé Research,
Lausanne, Switzerland
3Department of Nutrition and Dietary
recommendations, Société des Produits Nestlé
SA, Nestlé Research, Lausanne, Switzerland
4Department of Metabolic Health, Société des
Produits Nestlé SA, Nestlé Research,
Lausanne, Switzerland
Correspondence
Dr Joanne Hosking, Plymouth University
Peninsula Schools of Medicine and Dentistry,
N15 Plymouth Science Park, Plymouth PL6
8BX, UK.
Email: joanne.hosking@plymouth.ac.uk;
Dr François-Pierre, Department of Metabolic
Health, Société des Produits Nestlé SA, Nestlé
Research, Route du Jorat 57, 1000, Lausanne,
Switzerland
Email: francois-pierre.martin@rd.nestle.com
Funding information
Bright Future Trust; Diabetes UK; Earlybird
Diabetes Trust; Peninsula Foundation ; The
Kirby Laing Foundation
Abstract
Background:While insulin resistance (IR) is associated with specific metabolite signa-
tures in adults, there have been few truly longitudinal studies in healthy children,
either to confirm which abnormalities are present, or to determine whether they pre-
cede or result from IR. Therefore, we investigated the association of serum metabo-
lites with IR in childhood in the Earlybird cohort.
Methods: The Earlybird cohort is a well-characterized cohort of healthy children with
annual measurements from age 5 to 16 years. For the first time, longitudinal associa-
tion analyses between individual serum metabolites and homeostatic model assess-
ment (HOMA) of insulin resistance (HOMA-IR) have been performed taking into
account the effects of age, growth, puberty, adiposity, and physical activity.
Results: IR was higher in girls than in boys and was associated with increasing body
mass index (BMI). In longitudinal analysis IR was associated with reduced concentra-
tions of branched-chain amino acids (BCAA), 2-ketobutyrate, citrate and
3-hydroxybutyrate, and higher concentrations of lactate and alanine. These findings
demonstrate the widespread biochemical consequences of IR for intermediary
metabolism, ketogenesis, and pyruvate oxidation during normal child growth and
development.
Conclusions: Longitudinal analysis can differentiate metabolite signatures that pre-
cede or follow the development of greater levels of IR. In healthy normal weight chil-
dren, higher levels of IR are associated with reduced levels of BCAA, ketogenesis,
and fuel oxidation. In contrast, elevated lactate concentrations preceded the rise in
IR. These changes reveal the metabolite signature of insulin action during normal
growth, and they contrast with previous findings in obese children and adults that
represent the consequences of IR and obesity.
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1 | INTRODUCTION
Epidemic obesity has resulted in a rapid increase of type 2 diabetes
(T2D) in children.1-3 However, the pathways linking childhood obe-
sity to T2D remain poorly characterized, and prediction and preven-
tion of T2D are unfulfilled aspirations. Although insulin resistance
(IR) is important in the pathophysiology of T2D, the causes of IR in
children are complex, because they include both normal physiologi-
cal changes and weight gain. Therefore, there is a need to under-
stand the interplay of normal physiological factors and
pathophysiological parameters that contribute to IR in children. Met-
abolic phenotyping is now a well-established approach to character-
izing complex metabolic processes, and investigating the molecular
origins of IR in children.4
Metabolic phenotypes, or metabotypes, reflect systemic influ-
ences on molecular regulatory processes, including dietary and
physiological factors.5 In children, longitudinal analysis of
metabotypes has the potential to unravel the complex biochemis-
try of puberty, molecular disturbances associated with IR, and to
identify individuals at risk of T2D.6,7 In previous cross-sectional
studies of adults, branched chain and aromatic amino acid
metabotypes were consistently and positively associated with IR,
prediabetes and T2D, independently of adiposity.8 Furthermore, a
meta-analysis of eight prospective studies showed that each
study-specific SD difference in isoleucine, leucine, and tyrosine
was associated with a 36% higher risk of T2D. Similarly, valine and
phenylalanine were associated with 35% and 26% increased risk of
T2D, while glycine and glutamine were inversely associated with
T2D risk. These associations have led to the suggestion that
derangement of branched-chain amino acid (BCAA) catabolism may
be an important mechanism in the pathway to IR.
In order to test such hypotheses, longitudinal studies in children
are necessary. However, there have been very few truly longitudinal
studies in children. A review of 10 studies in children found that
BCAA, aromatic amino acids (AAA), and acylcarnitines were associated
with IR, and BCAA and tyrosine were associated with future meta-
bolic risk.9 However, most of these studies were cross-sectional in
predominantly obese children. In contrast, there has been a lack of
formal longitudinal studies of normal weight children. Therefore, it
remains uncertain whether the metabolic changes associated with IR
in reported studies represent cause or effect.
The EarlyBird study is a longitudinal cohort study of healthy chil-
dren, with annual clinical, anthropometric, and physiological assess-
ment from age 5 to 16 years. This study provides an ideal opportunity
for a detailed longitudinal metabonomic analysis investigating how
metabotypes relate to IR during childhood and adolescence. To our
knowledge, this is the first time the association between individual
metabolites and IR (homeostaticmodel assessment [HOMA] of insulin
resistance [HOMA-IR]) in childhood has been investigated in a
detailed longitudinal study, taking into account the effects of critical
covariates such as age, growth, puberty, adiposity, and physical
activity.
2 | METHODS
2.1 | Study population
We conducted the study in accordance with the ethical guidelines of
the Declaration of Helsinki II; ethics approval was granted by the
Plymouth Local Research Ethics Committee (1999), and parents gave
written consent and children verbal assent. The EarlyBird Diabetes
Study incorporates a 1995/1996 birth cohort recruited in 2000/2001
when the children were 5 years old (307 children, 170 boys).10 The
collection of data from the EarlyBird cohort is composed of several
clinical and anthropometric variables measured on an annual basis
from the age of 5 to the age of 16. Details on the measurement
methods are reported hereafter and in Supplementary Materials.
A first study was undertaken on 40 participants from age 5-14 years
(Study 1), and this was then extended to a full analysis of 150 participants
from age 5 to 16 (Study 2). In Study 1, 40 subjects were chosen on the
basis of having a complete set of samples available for analysis at each
time-point between 5 and 14 years (20 boys), having been stratified by
IR (1st and 4th quartile) at 5 and 14 years. This study was designed as a
pilot study to explore whether IR was associated with specific
metabotypes, HOMA-IR being used as an indicator of deterioration of
glucose control. The Study 2 aims at replicating the observations in
higher number of children, and extending the analysis till the age of
16 years when samples became available. In Study 2, subjects were pur-
posively selected to include all children who had shown impaired fasting
glucose (at one or more time-points during the course of the childhood
as reported previously11), and gender-matched normoglycemic children,
resulting in a total of 150 participants. Out of the 55 children who had
shown impaired fasting glucose in this subset, seven had a first degree
relative with T2D or T1D. Impaired fasting glycaemia has been selected
as an objective criterion to select children with an additional risk for
future diabetes. This resulted in the selection of 105 boys and 45 girls. In
Study 2, children had completed their visits at year 15 and 16, providing
a complete view on IR and glucose variations in adolescence. Twenty
children were common among the two studies.
2.2 | Clinical and anthropometric assessments
IR was determined each year from fasting glucose (Cobas Integra
700 analyzer; Roche Diagnostics, Basel, Switzerland) and insulin (DPC
IMMULITE, Siemens, California) (cross-reactivity with proinsulin, 1%)
using the homeostasis model assessment program,12,13 which has been
validated in children.14 BMI was derived from direct measurement of
height (Leicester Height Measure; Child Growth Foundation, London,
UK) and weight (Tanita Solar 1632 electronic scales), performed in blind
duplicate and averaged. BMI z-scores were calculated from the British
1990 standards.15 Moderate to vigorous physical activity (MVPA) was
measured annually from 5 years by accelerometry (Acti-Graph, Actigraph,
model7164, Computer Science and Applications Inc, Shalimar, Florida).16
Children were asked to wear the accelerometers for seven consecutive
days at each annual follow-up visit, and only recordings that captured at
least 4 days were used. Pubertal timing was evaluated by means of age
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at peak height velocity (APHV), determined as the tangential velocity at
the middle time point of three consecutive height measurements taken
6 months apart. Data are reported in Tables 1 and 2. Peripheral blood
was collected annually after an overnight fast, blood serum were stored
at −80C.
2.3 | Metabonomics
Serum samples collected from each child at every age between 5 and
16 years old were subjected to metabonomics. For technical feasibility
and to ensure optimal data reproducibility for cohort analysis, a
threshold of 1800 blood serum samples (eg, 150 different subjects)
was determined. Metabolic profiling was carried out by means of Pro-
ton nuclear magnetic resonance spectroscopy (1H NMR) spectros-
copy, as reported previously.6 Briefly, 400 μL of blood serum were
mixed with 200 μL of deuterated phosphate buffer solution 0.6 M
KH2PO4.
1H NMR metabolic profiles of serum samples were acquired
with a Bruker Avance III 600 MHz spectrometer equipped with a
5 mm cryoprobe at 310 K (Bruker Biospin, Rheinstetten, Germany)
and processed using TOPSPIN (version 2.1; Bruker Biospin) software
package. Based on an internal database of reference compounds, rep-
resentative signals of metabolites were integrated. The signals are
expressed in an arbitrary unit corresponding to a peak area normalized
to total metabolic profiles. 1H NMR spectroscopy being a quantitative
methods, metabolite peak area are proportional to metabolite concen-
trations, and thus their changes are representative of absolute change
in metabolite concentration in the serum. This metabonomics
approach covers major metabolic pathways, including lipoproteins,
amino acids, carboxylic acids, and central energy metabolism in a
highly reproducible manner across more than 1700 serum samples. In
particular, 1H-NMR spectrum of human blood serum enables the
monitoring of signals related to lipoprotein bound fatty acyl groups
found in triglycerides, phospholipids, and cholesteryl esters, together
with peaks from the glyceryl moiety of triglycerides and the choline
head group of phosphatidylcholine. In relation to technological devel-
opments, the analysis of Study 2 resulted in more sensitive 1H NMR
data and detection of a slightly greater number of low abundant
metabolites.
2.4 | Statistical analysis
The distribution of the outcome variable, IR, was skewed and so log-
transformed (Log IR) while each metabolite was transformed to a z-
score (ie, standardized with mean of 0 and SD of 1) for analysis. For
both Study 1 and Study 2, mixed effects modeling was used to assess
the association between individual metabolites and IR (HOMA-IR),
taking into account age, BMI z-scores, and physical activity. Control-
ling for maturational and growth status is crucial in life course studies,
and APHV is a key measure of maturity that was also taken into
account. Random intercepts were included as well as age (categorized
to allow for non-linear change in IR over time), gender, BMI z-score,
APHV, MVPA (number of minutes spent in moderate-vigorous physi-
cal activity), and individual metabolites (in separate models) as fixed
effects. Unadjusted and Bonferroni adjusted P-values are reported in
Tables 3 and 4. Because insulin was log transformed the
exponentiated coefficients represent the expected percent change in
IR associated with a unit (SD) change in metabolite. Because one
objective was to find replicated associations between studies, the
analysis conducted in Study 2 has been focused only on serum metab-
olites previously detected in Study 1 serum samples. Only succinate
was not consistently detected in all samples from Study 2 and there-
fore analysis not repeated. Results obtained on metabolites only
detected in Study 2 are provided in Supplementary Table 1.
TABLE 1 Characteristics of the cohort at 5y and 14y by gender
Boys Girls
Age (years) 5y 5.1 (4.8-5.3) 4.8 (4.7-5.0)
14y 13.9 (13.6-14.1) 13.8 (13.7-14.1)
BMI z-scores 5y −0.04 (−0.50-0.72) 0.40 (0.04-0.80)
14y 0.43 (−0.13-1.29) 0.78 (−0.05-1.48)
Moderate-vigorous
physical activity
(minutes/day)
5y 46.1 (34.1-67.1) 55.1 (44.9-62.5)
14y 52.4 (29.7-77.0) 42.7 (29.3-51.4)
Age at peak height
velocity (years)
13.4 (12.9-13.8) 11.9 (11.1-12.5)
IR (HOMA2-IR) 5y 0.47 (0.37-0.84) 0.85 (0.34-1.02)
14y 1.25 (0.56-1.63) 0.98 (0.78-2.23)
Note: Data are median (interquartile range).
Abbreviations: BMI, body mass index; HOMA-IR, homeostatic model
assessment of insulin resistance; IR, insulin resistance.
TABLE 2 Characteristics of the main cohort at 5y, 14y, and 16y
by gender
Boys Girls
Age (years) 5y 4.8 (4.7–5.0) 4.9 (4.8-5.1)
14y 13.8 (13.6-14.0) 13.9 (13.8-14.0)
16y 15.8 (15.6-16.0) 15.9 (15.8-16.1)
BMI z-scores 5y 0.09 (−0.48-0.80) 0.36 (−0.49-1.16)
14y 0.32 (−0.64-0.98) 0.85 (0.21-1.60)
16y 0.44 (−0.31-1.32) 0.70 (0.03-1.60)
Moderate-vigorous
physical activity
(minutes/day)
5y 53.1 (41.6-64.1) 40.1 (31.9-51.6)
14y 44.4 (30.7-63.14) 35.3 (18.4-50.4)
16y 43.9 (22.5-58.6) 27.0 (16.8-40.9)
Age at peak height
velocity (years)
13.0 (12.8-13.4) 11.6 (10.8-12.3)
IR (HOMA2-IR) 5y 0.49 (0.22-0.74) 0.76 (0.60-1.00)
14y 1.00 (0.79-1.47) 1.47 (1.00-1.70)
16y 0.70 (0.23-1.16) 0.84 (0.23-1.18)
Note: Data are median (interquartile range).
Abbreviations: BMI, body mass index; HOMA-IR, homeostatic model
assessment of insulin resistance; IR, insulin resistance.
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TABLE 3 Estimates and P-values from mixed effects models examining the association between metabolites and IR in Study 1 (n = 40)
Variable
ID Metabolites
1H NMR chemical shift of
the integrated signal (ppm) Coef SE
P-value
(unadjusted)
Bonferroni-
adjusted P-
value
1 Lipid (mainly HDL, fatty acid CH3 moieties) 0.83 −0.052 0.03 .08266 1.00
2 Lipid (mainly LDL, fatty acid CH3 moieties) 0.87 0.056 0.028 .04781 1.00
3 Leucine 0.96 −0.103 0.027 .00015 .01
4 Isoleucine 1.01 −0.045 0.026 .08713 1.00
5 Valine 1.05 −0.107 0.026 4.6E-05 .003
6 2-Ketobutyrate 1.07 −0.089 0.037 .01695 1.00
7 3-D-hydroxybutyrate 1.18 −0.106 0.027 .00013 .01
8 Lipid (mainly HDL, fatty acid CH3 moieties) 1.23 −0.012 0.03 .68734 1.00
9 Lipid (mainly LDL, fatty acid [CH2]n moieties) 1.27 0.087 0.028 .00227 .13
10 Lactate 1.33 0.067 0.025 .00719 .42
11 Alanine 1.48 0.085 0.024 .00044 .03
12 Lipid (mainly VLDL, fatty acid [CH2] moieties) 1.5 0.043 0.023 .06153 1.00
13 Arginine 1.71 −0.077 0.029 .00751 .44
14 Lysine 1.76 −0.024 0.023 .28897 1.00
15 Acetate 1.91 −0.01 0.025 .69837 1.00
16 N-acetyl proteins 2.03 0.024 0.028 .39399 1.00
17 Glutamate 2.12 −0.034 0.025 .17895 1.00
18 3-D-hydroxybutyrate 2.3 −0.084 0.024 .0004 .02
19 Glutamate 2.35 0.027 0.026 .31137 1.00
20 Glutamine 2.45 −0.04 0.026 .12765 1.00
21 Citrate 2.66 −0.132 0.028 3E-06 .0002
22 Asparagine 2.85 −0.028 0.025 .26311 1.00
23 Trimethylamine 2.87 −0.06 0.024 .01141 .67
24 Dimethylglycine 2.93 −0.046 0.026 .08207 1.00
25 Lysine 3 −0.06 0.027 .02559 1.00
26 Creatine 3.02 −0.095 0.029 .0011 .06
27 Citrulline 3.14 −0.081 0.032 .01143 .67
28 Phospholipids 3.21 −0.131 0.031 3.8E-05 .002
29 Glucose 3.25 −0.004 0.026 .88223 1.00
30 Trimethylamine-N-Oxide 3.25 −0.028 0.029 .32906 1.00
31 Taurine 3.29 −0.008 0.029 .78819 1.00
32 Proline 3.34 0.03 0.027 .26484 1.00
33 Glycine 3.57 0.007 0.03 .81812 1.00
34 Creatine 3.93 −0.058 0.033 .08599 1.00
35 Serine 3.96 −0.002 0.03 .93441 1.00
36 Threonine 4.26 0.013 0.023 .56905 1.00
37 Glucose 5.23 −0.003 0.025 .89908 1.00
38 Histidine 7.06 −0.049 0.026 .0588 1.00
39 Tyrosine 7.2 −0.005 0.026 .8485 1.00
40 Histidine 7.83 −0.057 0.027 .03601 1.00
41 Formate 8.45 −0.003 0.025 .91772 1.00
42 Succinate 2.39 −0.042 0.025 .09536 1.00
Note: Coef: Coefficient indicating the directions of the associations between the metabolite and Log IR overtime. Because insulin was log transformed the
exponentiated coefficients represent the expected percent change in insulin resistance associated with a unit (SD) change in metabolite. SE: standard error
for the coefficient.
Abbreviation: IR, insulin resistance; LDL, low density lipoproteinsl; VLDL, very low density lipoproteins.
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TABLE 4 Estimates and P-values from mixed effects models examining the association between metabolites and IR in Study 2 (n = 150)
Variable
ID Metabolites
1H NMR chemical shift of the
integrated signal (ppm) Coef SE
P-value
(unadjusted)
Bonferroni
adjusted P-
value
1 Lipid (mainly HDL, fatty acid CH3 moieties) 0.83 −0.059 0.024 .012 .96
2 Lipid (mainly LDL, fatty acid CH3 moieties) 0.87 0.108 0.023 <.0001 .0006
3 Leucine 0.96 −0.121 0.019 <.0001 <.0001
4 Isoleucine 1.01 −0.05 0.021 .0178 1.00
5 Valine 1.05 −0.114 0.02 <.0001 <.0001
6 2-Ketobutyrate 1.07 −0.071 0.019 .0003 .024
7 3-D-hydroxybutyrate 1.18 −0.092 0.018 <.0001 <.0001
8 Lipid (mainly HDL, fatty acid CH3 moieties) 1.23 0.052 0.021 .0156 1.00
9 Lipid (mainly LDL, fatty acid [CH2]n moieties) 1.27 0.133 0.023 <.0001 .00093
10 Lactate 1.33 0.101 0.019 <.0001 <.0001
11 Alanine 1.48 0.156 0.019 <.0001 <.0001
12 Lipid (mainly VLDL, fatty acid [CH2] moieties) 1.5 −0.12 0.022 <.0001 <.0001
13 Arginine 1.71 −0.116 0.021 <.0001 <.0001
14 Lysine 1.76 −0.112 0.019 <.0001 <.0001
15 Acetate 1.91 −0.088 0.028 .0016 .128
16 N-acetyl proteins 2.03 −0.046 0.022 .0398 1.00
17 Glutamate 2.12 −0.112 0.021 <.0001 <.0001
18 3-D-hydroxybutyrate 2.3 −0.118 0.019 <.0001 <.0001
19 Glutamate 2.35 0.042 0.024 .0847 1.00
20 Glutamine 2.45 −0.118 0.022 <.0001 <.0001
21 Citrate 2.66 −0.188 0.021 <.0001 <.0001
22 Asparagine 2.85 −0.115 0.021 <.0001 <.0001
23 Trimethylamine 2.87 −0.123 0.022 <.0001 <.0001
24 Dimethylglycine 2.93 −0.118 0.021 <.0001 <.0001
25 Lysine 3 −0.139 0.02 <.0001 <.0001
26 Creatine 3.02 −0.142 0.023 <.0001 <.0001
27 Citrulline 3.14 −0.137 0.022 <.0001 <.0001
28 Phospholipids 3.21 −0.066 0.024 .0067 .536
29 Glucose 3.25 −0.017 0.023 .4585 1.00
30 Trimethylamine-N-Oxide 3.25 −0.052 0.021 .0156 1.00
31 Taurine 3.29 −0.049 0.02 .0146 1.00
32 Proline 3.34 0.032 0.022 .1442 1.00
33 Glycine 3.57 −0.08 0.026 .0023 .184
34 Creatine 3.93 −0.121 0.025 <.0001 .00013
35 Serine 3.96 −0.134 0.022 <.0001 <.0001
36 Threonine 4.26 −0.026 0.017 .1129 1.00
37 Glucose 5.23 −0.008 0.022 .7038 1.00
38 Histidine 7.06 −0.136 0.021 <.0001 <.0001
39 Tyrosine 7.2 −0.008 0.02 .6885 1.00
40 Histidine 7.83 −0.124 0.022 <.0001 <.0001
41 Formate 8.45 NA NA NA NA
42 Succinate 2.39 NA NA NA NA
Note: Variable corresponding to succinate could not be integrated in Study 2. Coef: Coefficient indicating the directions of the associations between the
metabolite and Log IR overtime. Because insulin was log transformed the exponentiated coefficients represent the expected percent change in insulin
resistance associated with a unit (SD) change in metabolite. SE: standard error for the coefficient.
Abbreviation: IR, insulin resistance; LDL, low density lipoproteins; VLDL, very low density lipoproteins.
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To assess further which IR-associated metabolite may be an early
indicator of IR trajectories, we stratified the Study 2 population
according to low or high IR status over the 14-16 year age range.
Arbitrarily, the 91st centile for the HOMA-IR distribution was
employed as a threshold to define children with high IR status, similar
to the commonly used threshold for BMI z-score stratification of
weight status. Here, mixed effects modeling taking into account
covariates as described above, was used to assess the association
between specific metabolites and IR groups. Mixed effects modeling
not taking into account covariates are reported as Supplementary
Materials. Modeling was carried out in R software (www.R-project.
org) using the lmer function in the package lme417 and P-values calcu-
lated using the Satterthwaite approximation implemented in the
lmerTest package.18 Cross-sectional association between metabolites
and IR was assessed using Pearson's correlations at each age
(Supplementary Materials). Similarly, a year-on-year association of the
metabolites was assessed using Pearson's correlations (Supplementary
Materials).
3 | RESULTS
3.1 | Demographics
Clinical and anthropometrics characteristics of the children in Study
1 at 5 and 14 years are summarized in Table 1 and those in Study 2 at
5, 14, and 16 years in Table 2. For both genders there HOMA-IR
index decreased until around 8 years (Supplementary Figures 1a and
2a), which was followed by an increase through puberty, this trend
being dependent on the time of peak height velocity (age*APHV
interaction P < .001, Supplementary Figures 1b and 2b). IR was also
positively associated with BMI z-scores (P < .001).
3.2 | HOMA-IR and serum metabolite associations in
childhood
In Study 1, several metabolites including amino acids, organic acids,
and lipids showed a significant positive association with HOMA-IR in
longitudinal models, independently of BMI z-scores, physical activity
and APHV, and after multiple testing correction (Table 3). The out-
comes are repeated in the analysis conducted in Study 2 (Table 4).
Additional cross-sectional correlations between metabolites and
HOMA-IR, and year-to-year metabolite correlations are reported in
Supplementary Tables 2 and 3, for Study 2.
3.2.1 | Branched-chain amino acid metabolism
In Study 1, mixed effects models showed an inverse association of
valine and leucine with Log IR (P < .001), and a trend between isoleu-
cine and Log IR (P = .087). In Study 2, the inverse association of valine
and leucine with Log IR was confirmed (P < .001), and a weak inverse
association between isoleucine and Log IR was noted (P = .02). Cross-
sectional associations were variable according to time-point
(Supplementary Table 2). Cross-sectional correlations indicated an
inverse association between valine and Log IR, significant at 7, 11,
and 12 years; and with leucine at 7 and 9 years only. There were sta-
tistically significant correlations between isoleucine and Log IR, first
negative at 9 years, and then positive at 13 and 15 years. For leucine
and valine, there was also a statistically significant gender interaction
indicating that the observed association between these BCAA and
Log IR was dependent upon gender. Furthermore, year-to-year corre-
lations for valine, leucine, and isoleucine ranged from r = 0.06-0.58,
0.04-0.64, and 0.17-0.68 respectively, indicating that within-child
tracking of the BCAA varied with age (Supplementary Table 3). There
was little change over time in valine, leucine, and isoleucine.
Mixed effects modeling also captured the inverse association
between 2-ketobutyrate and Log IR in Study 1 (P < .01) and Study
2 (P < .001). The cross-sectional correlations between 2-ketobutyrate
and Log IR were statistically significant at 7, 9, and 11 years.
3.2.2 | Central energy-related metabolites
In Study 1 and Study 2, mixed effects modeling described statistically
significant inverse associations of citrate and 3-D-hydroxybutyrate
with Log IR, and positive associations of lactate and alanine with Log
IR (Tables 3 and 4). Cross-sectional correlation analyses revealed neg-
ative associations at each time point between citrate and Log IR from
age 5 to 16, and between 3-D-hydroxybutyrate and Log IR from age
5 to 15 (Supplementary Table 2). In addition, Log IR was positively
correlated with alanine at each time point from age 5 to 9, 11 and
12 years. Lactate was positively associated with Log IR at 7 years,
9 years, and each time point from age 11 to 16.
Furthermore, year-to-year correlations for alanine, lactate, 3-D-
hydroxybutyrate and citrate ranged from r = 0.01-0.60, 0.12-0.56,
0.24-0.47, and 0.27-0.66 respectively, indicating that within-child
tracking of the metabolite varied with age (Supplementary Table 3).
3.2.3 | Lipid related metabolites associated with IR
In both Study 1 and Study 2, signals derived from the methyl fatty acyl
groups in phospholipids containing choline showed inverse associa-
tions with Log IR, whereas signals derived from the methyl fatty acyl
groups in low density lipoproteins (LDL) particles showed positive
associations with Log IR. Cross-sectional associations between phos-
pholipids and Log IR were inverse and statistically significant from age
7 to 16 years, whereas those between Log IR and fatty acyl groups in
LDL particles were positive and statistically significant between 7 and
14 years. Furthermore, year-to-year correlations for phospholipids
were very high ranging from r = 0.46-0.78 (Supplementary Table 3).
3.2.4 | Amino acid metabolism
Mixed effects modeling identified significant inverse associations
between histidine, creatine, arginine, citrulline, and lysine with Log IR
in Study 1 and Study 2. Each metabolite also showed inverse cross-
sectional correlations with Log IR. Correlations were significant for
histidine between 9 and 13 years; creatine at 7, 9, 11, and 12 years;
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arginine at 7, 8, and 12 years; citrulline between 8 and 16 years, and
lysine between 7 and 16 years. Furthermore, year-to-year correlations
for histidine and creatine were ranging from r = 0.19-0.70 and
r = 0.25-0.71, respectively (Supplementary Table 3).
3.3 | Metabolites according to high IR status (91st
centile) at 14-16 years
For each metabolite showing a significant longitudinal association
with Log IR, we investigated whether their serum concentrations were
informative for high IR status over the 14-16-year age range. Arbi-
trarily, the 91st centile for the HOMA-IR distribution was selected as
a threshold to define high IR status. Mixed effects modeling not
corrected for covariates (gender, age, BMI z-scores, physical activity,
and APHV) identified a significant positive association between lac-
tate and Log IR (P < .001), and fatty acyl groups in LDL (P < .005). Fur-
ther, a significant negative association was found between Log IR and
very low density lipoproteins (VLDL) particles (P = .03), acetate
(P = .006), citrate (P = .006), asparagine (P = .002), trimethylamine
(P = .001), dimethylamine (P = .004), lysine (P = .005), citrulline
(P = .007), glycine (P = .006), histidine (P = .015), and 3-D-
hydroxybutyrate (P = .04). Fat mass (waist circumference) was also a
statistically significant variable which increased in the high Log IR
group over time (P = 2.610−5). However, when correcting for main
covariates, only the association between lactate and Log IR remained
significant (Supplementary Table 4). BMI z-score was an important
F IGURE 1 Selected metabolites from 5y to 16y according to classification of IR between 14y and 16y (at least one occurrence of insulin
resistance ≥91st centile)
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covariate influencing the other observed associations. The temporal
profiles of selected parameters are reported in Figure 1 and supple-
mentary Figure 3.
4 | DISCUSSION
In this uniquely well-characterized cohort of healthy children, relative
increases in IR are accompanied by a complex molecular signature in
central energy pathways, amino acid and fatty acid metabolism. This
suggests that higher levels of IR are associated with age-dependent
molecular changes throughout normal growth and adolescence. The
findings add to, contrast with, and significantly extend the existing
literature.
Previous studies observed positive associations between BCAA
concentrations and IR. In this study, Log IR was inversely associated
with BCAA and 2-ketobutyrate. This difference may be because most
previous studies were undertaken in adults.19-23 In contrast, a series
of relatively small studies have been reported in children,24-34 and
with limited exceptions most of these were cross-sectional. In the
mainly cross-sectional studies of obese children included in the sys-
tematic review of Zhao et al, IR was found to be positively associated
with BCAA.9 Notwithstanding the limitations of these studies, the
associations resemble those found in adults.19-22,35 Therefore, our
findings in mainly normal weight healthy children may differ from
studies in overweight and obese children and adults. In our study, only
when stratifying children according to a 91st centile of HOMA-IR at
14 to 16 years of age, BCAA levels tended to be positively associated
with Log IR, yet not significantly. As pointed out by McCormack,30
obesity may strongly influence BCAA levels by multiple mechanisms
(over nutrition, protein, and lipid metabolism) associated with IR. In
normal weight children, however, metabolism of BCAA may be differ-
ent due to lower insulin levels and the predominant effects of normal
growth and development.
Several unifying models have been proposed to explain associa-
tions between multiple metabolites and IR. Adams postulated a pivotal
role for the mitochondrial enzyme Branched Chain Keto acid Dehy-
drogenase (BCKD) in the generation of elevated BCAA and branched
chain keto acids in IR and obesity.35 Furthermore, impairment of
BCKD activity has been proposed as an explanation for elevated con-
centrations of aromatic and sulfated amino acids, 3-D-
hydroxybutyrate and 2-ketobutyrate, all of which have also been
observed in individuals with IR and obesity.35 In our study, 3-D-
hydroxybutyrate and 2-ketobutyrate were inversely associated with
IR. However, phenylalanine, methionine, and cysteine could not be
reliably quantified, and there was no significant association between
tyrosine and Log IR. These observations suggest that metabolite-IR
associations are different in insulin sensitive healthy children with
normal body fat, and/or they change during childhood, depending on
age, and changes in weight and IR. Many of the previously reported
metabolite associations are likely to be consequences of weight gain
and/or IR. The present findings are consistent with the proposal that
healthy insulin sensitive children have intact BCKD activity and
oxidize BCAA efficiently, whereas weight gain and IR impair BCKD
activity and result in elevated BCAA.
The present study also suggests that IR is associated with several
other disturbances in central energy pathways. Insulin resistance is
associated with impaired metabolite flux through the Krebs cycle.35
Consistent with this, we found that citrate was inversely associated
with log IR. Decreased citrate levels may indicate a decreased contri-
bution of fatty acids to the pool of acetyl-coA entering the Krebs
cycle. We also observed that reduced 3-D-hydroxybutyrate concen-
trations were associated with Log IR, perhaps indicating decreased
lipolysis and fatty acid oxidation. Recently, Mastrangelo et al observed
reduced 3-D-hydroxybutyrate in obese prepubertal children with IR,36
an observation perhaps attributable to hyperinsulinemia. It is possible
to speculate that a reduced capacity to generate ketones might have
significant long term implications for body weight regulation.
In addition, in longitudinal analysis higher alanine and lactate levels
were associated with Log IR throughout childhood. Such a signature
also occurs in obese prepubertal children with IR.29 This pattern may
reflect enhanced mitochondrial pyruvate oxidation secondary to
reduced fatty acid oxidation under conditions of lower intra-
mitochondrial NADH/NAD+ and acetyl-CoA. This observation also
suggests IR is associated with increased flux through the Cahill and
Cori cycles in the liver and muscle. In particular, subjects in the 91st
centile of HOMA-IR in adolescence exhibited increasing lactate levels
from 7 years of age, suggesting that elevated lactate levels might be
an early precursor of IR.
Lastly, this analysis identified novel negative associations of his-
tidine, lysine and arginine concentrations with Log IR. Interestingly,
subjects in the 91st centile of HOMA-IR adolescence exhibited
lower histidine levels at ages 9, 13, 14, and 15 years, which cor-
responded to the period where Log IR trajectories diverged between
groups. When stratifying children at the 91st centile of HOMA-IR at
14 to 16-year of age, histidine levels were lower in children with
higher Log IR at ages 9, 13, 14, and 15. However, the association
was not significant after adjustment for BMI z-score, suggesting it is
a weight-related effect. Because BMI z-scores increase from child-
hood to adolescence, and this is a factor influencing IR, it is not sur-
prising that metabolic signatures are influenced by body
composition. Histidine has been identified previously as a marker of
IR in obese adults, with potential roles in inflammation and oxidative
stress,36 especially in obese adult women with the metabolic syn-
drome.37 Histidine supplementation has also been shown to reduce
IR,38 possibly by protecting against oxidative stress in adipose tissue,
stimulation of adiponectin secretion from adipocytes, and improving
release of fatty acids from adipocytes during lipolysis.38 The reason
for the inverse association of histidine with IR in this study remains
uncertain, but it is possible that low histidine levels might contribute
to weight-related changes in IR and oxidative stress. Furthermore,
the anthropometric and metabolic changes diverge between groups
around the APHV, indicating puberty as a critical period shaping the
molecular phenotype.
This study, as well as all of the previous studies of children
reported in the literature, has certain limitations. These include
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subject selection, limited sample sizes, limited phenotypic data on
growth. However, a significant strength of EarlyBird is that it is a truly
longitudinal study of a cohort of healthy children, with detailed annual
biochemical and phenotypic measurements from age 5 to 16 years.
Importantly, the majority of the children were of normal weight and
the IR observed was within the normal physiological range. Therefore,
the EarlyBird study is not expected to reveal the consequences of
more severe obesity or IR, rather it provides insights into the begin-
ning of these conditions. Our observations are subject to replication,
especially for the BCAA results which show a negative relationship
with IR. The inclusion of healthy children who were of normal weight
and insulin sensitivity reduces the variance of IR in the study popula-
tion, and hence differences may be more difficult to demonstrate. The
HOMA method may also have certain limitations as a measure of IR,
although it has been shown to correlate highly with clamp-derived
measurements.14 Finally, the duration of follow-up, although 10 years
long, may not yet be sufficient to detect the long-term emergence of
obesity and IR. Therefore, longer term follow-up of the cohort will
provide further opportunities to examine the predictive value of these
biomarkers.
In conclusion, this unique longitudinal study of healthy, predomi-
nantly normal weight, children shows that IR is associated with a
characteristic molecular phenotype, including lower levels of BCAA,
Krebs cycle intermediates and ketogenesis, and increased activity of
Cori and Cahill cycles, while elevated lactate concentrations were
found to precede IR. These findings reveal the broad functional rela-
tionship between insulin action and multiple pathways of energy
metabolism during normal child growth and development. Moreover,
the directions of observed associations suggest that most previously
reported findings, including elevated BCAA concentrations in obese
children, are consequences of IR and obesity. In the context of child-
hood obesity, however, impaired oxidation of BCAA, glucose and
fatty acids, and reduced ketogenesis, are all likely to be maladaptive,
and liable to perpetuate the obese condition and predispose to dia-
betes. The findings also suggest that reduced concentrations of his-
tidine might be of pathophysiological significance. Finally, Neel
postulated that normal insulin sensitivity evolved to maintain effi-
cient metabolic homeostasis and adaptation, whereas modern-day
obesity resulted in IR and hyperinsulinemia, which were maladaptive
and predisposed to diabetes.39 Our findings broadly support this
hypothesis.
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